Atrial fibrillation remains a common and challenging cardiac arrhythmia, particularly in hypertensive patients, who face a ...

Abbott (ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving ...

Medtronic (MDT) announced positive clinical outcomes from two studies in atrial fibrillation, AFib, patients treated with the Affera family of ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

One-year clinical trial data for the next-generation, investigational, Sphere-360TM single-shot PFA catheter show impressive safety, perf ...

PFA therapy works differently from traditional cardiac ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac t ...

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt PFA SystemThe 12-month results of the ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Abbott (NYSE: ABT) today announced new study data demonstrating the safety and efficacy of its Volt pulsed field ablation ...

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...